Free Trial

Halozyme Therapeutics (HALO) News Today

Halozyme Therapeutics logo
$54.43 +0.01 (+0.02%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$54.46 +0.04 (+0.06%)
As of 05/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HALO Latest News

High Growth Tech Stocks To Watch In The US May 2025
Halozyme Therapeutics, Inc. stock logo
Armis Advisers LLC Invests $295,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Armis Advisers LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,177 shares of the biopharmaceutical company's stock, valued at approximately $295,000. Ot
Halozyme Therapeutics, Inc. stock logo
Two Sigma Investments LP Has $11.81 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Two Sigma Investments LP boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 403.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,030 shares of the bio
Halozyme Therapeutics, Inc. stock logo
Novem Group Invests $841,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Novem Group purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 17,586 shares of the biopharmaceutical company's stock, valued at appro
Halozyme Therapeutics, Inc. stock logo
ProShare Advisors LLC Buys 10,531 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
ProShare Advisors LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,114 shares of the biopharmaceutical company's sto
Halozyme Therapeutics, Inc. stock logo
Steamboat Capital Partners LLC Buys 75,890 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Steamboat Capital Partners LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 43.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 249,751 shares of the biop
Halozyme Therapeutics, Inc. stock logo
Nuveen Asset Management LLC Sells 8,634 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Nuveen Asset Management LLC lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,530,519 share
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned a consensus rating of "Hold" from the twelve brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and
Halozyme Therapeutics, Inc. stock logo
Rafferty Asset Management LLC Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Rafferty Asset Management LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 219,392 shares of the biopharmaceutical company'
Halozyme Therapeutics, Inc. stock logo
Point72 Europe London LLP Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Point72 Europe London LLP bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 29,335 shares of the biopharmaceutical company's stock, valued at approximat
Halozyme Therapeutics, Inc. stock logo
Redwood Investments LLC Has $1.54 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Redwood Investments LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,189 shares
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Lowered by Leerink Partnrs
Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday.
Halozyme Therapeutics, Inc. stock logo
Janus Henderson Group PLC Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Janus Henderson Group PLC increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 702,085 shares of the biopharmaceutical company's stock after purchasing an additional 156,912 sh
Halozyme Therapeutics, Inc. stock logo
Panoramic Capital LLC Makes New $2.62 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Panoramic Capital LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 54,821 shares of the biopharmaceutical company's stock,
Halozyme Therapeutics, Inc. stock logo
Captrust Financial Advisors Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Captrust Financial Advisors increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,862 share
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics (NASDAQ:HALO) Cut to Underperform at Leerink Partners
Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a report on Tuesday.
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 171.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 831,414 shares of the biopharmaceutical company's stock after
Halozyme Therapeutics, Inc. stock logo
Algert Global LLC Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Algert Global LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,900 shares of the biopharmaceutical company's stock, valued
Halozyme Therapeutics, Inc. stock logo
CoreCap Advisors LLC Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
CoreCap Advisors LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,831 shares of the biopharmaceutical company's stock after pur
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Benchmark to "Hold"
Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday.
Halozyme Therapeutics, Inc. stock logo
Clark Capital Management Group Inc. Has $8.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Clark Capital Management Group Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 30.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 178,827 shares of the biopharmaceutical comp
Halozyme Therapeutics, Inc. stock logo
Centiva Capital LP Takes $643,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Centiva Capital LP purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,450 shares of the biopharmac
Halozyme Therapeutics, Inc. stock logo
Brevan Howard Capital Management LP Invests $1 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Brevan Howard Capital Management LP purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,996 shares of the
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High After Earnings Beat
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High on Better-Than-Expected Earnings
Halozyme Therapeutics, Inc. stock logo
Wells Fargo & Company Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $65.00
Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday.
Halozyme Therapeutics, Inc. stock logo
Axa S.A. Purchases 23,835 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Axa S.A. increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 22.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,891 shares of the biopharmace
Halozyme Therapeutics, Inc. stock logo
Stifel Financial Corp Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Stifel Financial Corp raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,768 shares of the biopharmaceutical company's stoc
Halozyme Therapeutics, Inc. stock logo
Cary Street Partners Financial LLC Invests $4.74 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Cary Street Partners Financial LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 99,154 shares of the biopharmaceut
Halozyme Therapeutics, Inc. stock logo
Marshall Wace LLP Invests $212,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,426 shares of the biopharmaceutical company's st
Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

HALO Media Mentions By Week

HALO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HALO
News Sentiment

1.06

0.87

Average
Medical
News Sentiment

HALO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HALO Articles
This Week

7

11

HALO Articles
Average Week

Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:HALO) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners